ibritumomab tiuxetan
Zevalin	Pharmaceutical company: Spectrum Pharmaceuticals, Inc. www.zevalin.com

NEW INDICATION & DOSAGE
Previously untreated follicular non-Hodgkin's lymphoma in patients who achieve a partial or complete response to first-line chemotherapy—
Adults: On day 1, premedicate with acetaminophen 650 mg P.O. and diphenhydramine 50 mg P.O. Give rituximab 250 mg/m² by I.V. infusion at 50 mg/hour. If no reaction, increase in 50 mg/hour increments every 30 minutes to a maximum dose of 400 mg/hour. Next, administer 5 mCi indium-111 ibritumomab tiuxetan I.V. over 10 minutes within 4 hours of rituximab infusion.
   On day 7, 8, or 9, premedicate with acetaminophen 650 mg P.O. and diphenhydramine 50 mg P.O. Give rituximab 250 mg/m² by I.V. infusion at 100 mg/hour. Increase by 100 mg/hour at 30-minute intervals to a maximum dose of 400 mg/hour. If infusion reactions occurred during rituximab infusion on day 1 of treatment, administer at an initial rate of 50 mg/hour and increase by 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour. Give Y-90 ibritumomab I.V. through a free-flowing I.V. line within 4 hours of rituximab infusion. If platelet count is 150,000/mm³ or greater, administer Y-90 ibritumomab 0.4 mCi/kg of actual body weight I.V. over 10 minutes. If platelet count is 100,000 to 149,000/mm³ in relapsed or refractory patients, give Y-90 ibritumomab 0.3 mCi/kg of actual body weight I.V. over 10 minutes.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins,
publisher of Lippincott's Nursing Drug Guide.
For help on how you should use this site, see our Disclaimer.

© Copyright 2010 by Lippincott Williams & Wilkins